Hint mode is switched on Switch off
For swift navigation between sections

Organization: ANI Pharmaceuticals
LEI 5493000T6CXTND40YH31

Organization name
ANI Pharmaceuticals, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Bond debt
-

explore the most comprehensive database

800 000

bonds globally

Over 400

pricing sources

80 000

stocks

9 000

ETF

track your portfolio in the most efficient way
Bond Search
Watchlist
Excel ADD-IN
Get access
×

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Register
×

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs
Get full access to the platform from any device & via Cbonds app
Enhance your portfolio management with Cbonds Excel Add-in
Build yield maps, make chart comparison within a click
Don't wait any longer — start using Cbonds today! Register

Latest data on

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

ANI Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals. The company manufactures oral solid dose products, as well as liquids and topicals, narcotics, and potent products; and Lithobid lithium carbonate extended release tablets. Its targeted areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products.

Awards

News

17/04/2024 ANI Pharmaceuticals: Results Of Operations And Financial Condition, Regulation Fd Disclosure, Exhibits
12/03/2024 ANI Pharmaceuticals: Results Of Operations And Financial Condition, Regulation Fd Disclosure, Exhibits
29/02/2024 ANI Pharmaceuticals: Results Of Operations And Financial Condition, Exhibits
21/02/2024 Moody's Investors Service revised outlook on ANI Pharmaceuticals to positive and affirmed at "B2" (LT- foreign currency) credit rating
21/02/2024 Moody's revises ANI Pharmaceuticals' outlook to positive; affirms B2 CFR (Rating action commentary)
All organization news

Documentation

IFRS/US GAAP reports

2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Bond debt by currency

Show more Hide

Codes

  • LEI
    5493000T6CXTND40YH31
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001023024
  • EIN
    58-2301143

Credit and ESG Ratings

Macroeconomic Indicators - ANI Pharmaceuticals

Registration is required to get access.